1-11 of 11
Kejal Jadhav
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Gaurav Vadnerkar, Joan Clements, Mel Mann, Vainavika Reddy Gaddam, Chaitali Nag, Shiva Padhi, David Wei, Marcello Azolino, Kejal Jadhav, Daisy Yang, Andrea Damon, Islam Sadek
Journal: Blood
Blood (2024) 144 (Supplement 1): 5192.
https://doi.org/10.1182/blood-2024-199951
Published: 2024
Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota
Journal: Blood
Blood (2024) 144 (Supplement 1): 2434.
https://doi.org/10.1182/blood-2024-201831
Published: 2024
Journal Articles

ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs

Anchit Khanna, Hannah Small, Dhamend Lutchman, Rafael Erlich, Gabriel Marquez, Daisy Yang, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 4527.
https://doi.org/10.1182/blood-2024-201022
Published: 2024
Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 3812.
https://doi.org/10.1182/blood-2024-193201
Published: 2024
Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn
Journal: Blood
Blood (2024) 144 (Supplement 1): 7913.
https://doi.org/10.1182/blood-2024-207213
Published: 2024
Journal Articles

Efficacy, Safety, and Treatment-Free Remission Outcomes of Front-Line Chronic Myeloid Leukemia Treatments - a Systematic Literature Review

Isabelle Lundqvist, Shaun Walsh, Nikunj Dobariya, Petya Kodjamanova, Kejal Jadhav, Pauline Gilbert
Journal: Blood
Blood (2024) 144 (Supplement 1): 7643.
https://doi.org/10.1182/blood-2024-205494
Published: 2024
Journal Articles

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Ira Zackon, April Beeks, David Wei, Chuck Wentworth, Jinhong Guo, Courtney McDermott, Kejal Jadhav, Lisa Herms, Andrea Damon, Islam Sadek, Christopher B. Benton
Journal: Blood
Blood (2024) 144 (Supplement 1): 6611.
https://doi.org/10.1182/blood-2024-210681
Published: 2024
Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5190.
https://doi.org/10.1182/blood-2023-180789
Published: 2023
Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5098.
https://doi.org/10.1182/blood-2023-180772
Published: 2023
Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Ehab L. Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guerin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 1809.
https://doi.org/10.1182/blood-2023-178722
Published: 2023
Journal Articles

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Sudipto Mukherjee, Chi-Chang Chen, Magdaliz Gorritz, Islam Sadek, Serban Iorga, Zifan Zhou, Jing He, Rodrigo Maegawa, Andrea Damon, Germano Ferreira, Kejal Jadhav
Journal: Blood
Blood (2022) 140 (Supplement 1): 13297–13298.
https://doi.org/10.1182/blood-2022-166473
Published: 2022